Investigation on the Epidemic Prevention Effect of Using Chinese Medicine During the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Outbreak.
Taipei City Hospital Linsen Chinese Medicine and Kunming Branch
1 other identifier
observational
2,000
1 country
1
Brief Summary
Taking a regional hospital as an example, the investigators will discuss the changes in the community cumulative incidence rate(CIR) and the epidemic prevention effect of using Chinese medicine during the SARS-CoV-2 outbreak. Main purpose: Retrospective case study to explore the effect of traditional Chinese medicine on the prevention of SARS-CoV-2. Secondary purpose: If there are related side effects after taking Chinese medicine.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2020
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 31, 2021
CompletedFirst Submitted
Initial submission to the registry
November 18, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
November 18, 2021
CompletedFirst Posted
Study publicly available on registry
February 11, 2022
CompletedMarch 2, 2022
February 1, 2022
1.6 years
November 18, 2021
February 12, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Investigation on the effect of using traditional Chinese medicine to prevent SARS-CoV-2 infection in two groups with cumulative incidence rate(CIR).
Compare the dangerous states within two groups with CIR.
18 months
Study Arms (2)
JGF (Jing-Guan-Fang): Traditional Chinese Medicine Decoction
JGF group: 100ml JGF decoction per day at least 1 week
NO JGF
NO JGF group: None use traditional Chinese medicine(JGF)
Interventions
Use 100ml JGF decoction per day as a preventive measure for patients with COVID-19.
Eligibility Criteria
The subjects of this study are patients who went to the Taipei City Hospital Linsen Chinese Medicine and Kunming Branch from January 1, 2020, to July 31, 2021. It is estimated that the medical records of 1,000 patients who use traditional Chinese medicine for new coronary pneumonia prevention and control will be collected as the experimental group, and they will be randomly matched. The medical records of 1,000 patients who have not used Chinese medicine as a control group for the prevention of new coronary pneumonia, a total of 2,000.
You may qualify if:
- \- From January 1, 2020 to July 31, 2021, Chinese medicine is used for patients with new coronary pneumonia epidemic prevention.
You may not qualify if:
- Patients who do not use traditional Chinese medicine for the prevention of new coronary pneumonia.
- Patients who have signed and refused to provide medical records.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Taipei City Hospital
Taipei, 886, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor
Study Record Dates
First Submitted
November 18, 2021
First Posted
February 11, 2022
Study Start
January 1, 2020
Primary Completion
July 31, 2021
Study Completion
November 18, 2021
Last Updated
March 2, 2022
Record last verified: 2022-02